USPSTF Reaffirms Early Pregnancy Screening for Syphilis

The United States Preventive Services Task Force (USPSTF) has officially reiterated its recommendation for routine syphilis screening during pregnancy. This endorsement, published on May 13, 2025, in the Journal of the American Medical Association, underscores the ongoing importance of early detection and treatment of syphilis to prevent congenital infections.

The update is based on a comprehensive review of recent evidence concerning the benefits and potential harms of screening and treatment. Experts, including Dr. Gary N. Asher from the University of North Carolina at Chapel Hill, reaffirm that early, universal screening for syphilis in pregnant individuals provides a significant net benefit. The review notes that no new data has emerged to challenge or alter the previous guidelines.

Recent studies involving over 51,000 participants examined the potential harms of screening, which include false positives and adverse reactions to penicillin treatment. False-positive rates vary considerably depending on the screening method, especially when utilizing a reverse-sequence two-step process. Treatment-related reactions occurred in roughly 2.5% of cases.

The USPSTF emphasizes that clinicians should conduct syphilis screening as early as possible during pregnancy. If screening occurs later, it should be repeated at the earliest opportunity if not done initially. The goal is to reverse the rising trend of congenital syphilis cases by adhering to established screening protocols and addressing systemic barriers that hinder effective management.

Overall, the evidence strongly supports early screening as a crucial strategy in safeguarding maternal and infant health. Healthcare providers are encouraged to maintain high screening fidelity and ensure timely intervention to prevent congenital syphilis.

For more detailed insights, refer to the original publication in JAMA (2025).